A Multi-Site Study Comparing a Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Eravacycline using **Fastidious Organisms**

*N. M. Holliday¹, C. C. Knapp¹, S. M. Andrus¹, S.B. Killian¹, T.C. Lewis¹, J.M. Lindley², J. M. Streit², B.J. Olson³, T.R. Fritsche³, K.Becker⁴, E.A. Idelevich⁴, E. Scopes⁵, A.M. Leonte⁵, C.fyfe⁶ ¹Thermo Fisher Scientific, Cleveland, OH; ²JMI Laboratories, North Liberty, IA; ³Marshfield Clinic, Marshfield, WI; ⁴University Hospital Münster, Germany; ⁵Thermo Fisher Scientific, Basingstoke, UK; ⁶Tetraphase Pharmaceuticals, Watertown, MA

Abstract

Background: Eravacycline (ERV) (Tetraphase Pharmaceuticals, Watertown, MA) is a novel, fully-synthetic fluorocycline displaying broad spectrum activity against a variety of organisms. A 4-site study was performed to determine the accuracy and reproducibility of ERV susceptibility testing against Streptococcus spp. and Haemophilus influenzae using the Thermo Scientific[™] Sensititre® dried MIC susceptibility system (Thermo Fisher Scientific, Cleveland, OH) compared with the CLSI (M07) reference broth microdilution method (BMD).

Methods: ERV (0.002-16µg/mL) was tested against 537 recent clinical isolates, 118 challenge isolates, and 15 reproducibility isolates of *Streptococcus* spp. These isolates consisted of S. pneumoniae (253), S. pyogenes (121), S. agalactiae (130), S. mitis group (62), S. salivarius (35), S. anginosus group (69). ERV (0.001-16µg/mL) was also tested against 393 recent clinical isolates, 50 challenge isolates, and 10 reproducibility isolates of *H. influenzae* (beta lactamase positive and negative). The Sensititre MIC susceptibility system was inoculated per manufacturers' instructions, and the BMD method was performed per CLSI guidelines. Quality control organisms were tested daily and were within acceptable ranges.

Results: Comparison of Streptococcus spp. MIC results on the Sensititre system to the CLSI BMD method for automated and manual reads resulted in 99.4% and 99.2% essential agreement (EA, +/- 1 log₂ dilution) for ERV, respectively. Overall the essential agreements for reproducibility (+/- 1 log₂ dilution of the modal MIC) using automated and manual reads were 98.5% and 98.9%. Comparison of *H. influenzae* MIC results on the Sensititre system to the CLSI BMD method for manual read methodology resulted in 98.6% essential agreement (EA, +/- 1 log₂ dilution) for ERV. Overall agreements for reproducibility (+/- 1 log₂ dilution of the modal MIC) using manual read methodology was 100%.

Conclusion: The Sensititre susceptibility system demonstrates an equivalent level of performance compared to the CLSI BMD method when testing ERV against fastidious organisms, specifically Streptococcus spp., and H. influenzae. The high level of agreement obtained by the Sensititre susceptibility system and the CLSI BMD method suggests that this is an acceptable method for susceptibility testing of ERV.


Introduction Eravacycline (Figure 1.) (Tetraphase Pharmaceuticals, Watertown, MA) is a novel, fully-synthetic fluorocycline displaying broad spectrum activity against a variety of organisms. This in vitro multi-site comparison study was conducted to evaluate the performance of Streptococcus spp. and Haemophilus influenzae (beta lactamase positive and negative) with eravacycline on the commercially manufactured Sensititre® 18-24 hour susceptibility system compared against the Clinical Laboratory Standards Institute (CLSI) reference broth microdilution method (BMD) (M07/M100). To establish equivalency, a four lab clinical study was conducted, and the MIC results obtained using the Sensititre dried plate technology were compared to the MIC results obtained from the CLSI M07 frozen reference plate.

Materials and methods

•The Sensititre 18-24 hour MIC or breakpoint susceptibility system (Thermo Fisher Scientific, Oakwood Village, OH) is an in vitro diagnostic product for clinical susceptibility testing of both fastidious and non-fastidious organisms.

Eravacycline was tested against: (Table 1.)

- 537 recent Streptococcus spp. and 393 Haemophilus influenzae clinical isolates across the four sites
- 118 Streptococcus spp. and 50 Haemophilus influenzae challenge isolates at a single testing site
- 15 Streptococcus spp. and 10 Haemophilus influenzae reproducibility isolates at each site (tested in triplicate over a 3 day testing period)
- 2 Quality Control Strains (ATCC)



Materials and Methods Cont.			Results			Results Cont.				
 Colony Counts and purity plates were performed on the inoculums of the clinical, challenge, reproducibility and QC strains on each day of testing. Each isolate was tested using a: Dried Sensititre 18–24 susceptibility plate containing eravacycline (0.002-16µg/ml) for <i>Streptococcus</i> spp. and (0.001-16µg/ml) for <i>Haemophilus influenzae</i>. The dried plates for <i>Streptococcus</i> spp. were set up and tested according to the manufacturer's instructions. Both automated and manual reading methodologies for <i>Streptococcus</i> spp. were employed. The dried plates for <i>Haemophilus influenzae</i> were set up and tested according to the manufacturer's instructions and was manual read only. CLSI reference broth microdilution plate was prepared and tested on each isolate according to the current Clinical Laboratory Standards Institute standard method. 			Clinical Isolates and Challenge Organisms The overall essential agreement for Streptococcus spp. within ±1 log2 dilution was 99.2% for the manual method and 99.4% for the auto read method. The overall essential agreement for Haemophilus influenzae within ±1 log2 dilution was 98.6% for the manual method. Inter-laboratory Reproducibility Reproducibility testing results for Streptococcus spp. within ±1 log2 dilution from the modal MIC was 98.5% for the auto read method and 98.9% for the manual read method. (Table 5.) Reproducibility testing results for Haemophilus influenzae within ±1 log2 dilution from the modal			Table 5. Inter-laboratory Reproducibility for Streptococcus spp. % Essential Agreemer $\pm 1 \log_2$ dilution from the Modal Value				
						Eravacycline	Auto Read	Manual Re		
						Between-site total isolates tested	540	540		
						Between-site isolates within +/- 1 well from mode	532	533		
						Between-site reproducibility ratio	532	533		
						Between-site reproducibility %	98.5%	98.9%		
able 1. Organisms Tested		Number Tested	MIC was 100.0% for the manual read method. (Table 6.)			Total essential agreement	532/540	533/54		
linical Isolates (4 sites) treptococcus spp.		537	Essential agreement for eravacycline on the Sensititre susceptibility plate compared to the reference microdilution plate was calculated for each read method using the +/- one log ₂				Essential agreement %	<u>98.5%</u>	<u>98.9%</u>	
Haemophilus influenzae		393	dilution standard. Essential agreement rates for <i>Streptococcus</i> spp. are shown in Table 3 . Essential agreement rates for <i>Haemophilus influenzae</i> are shown in Table 4 . (manual read only).				Table 6. Inter-laboratory Reproducibility for Haemophilus influenzae. % EssentialAgreement $\pm 1 \log_2$ dilution from the Modal Value			
CDC Challenge Isolates (one site) Streptococcus spp.		118	Table 3. Summary Data and % Essential Agreement of Streptococcus spp.			Eravacycline	Manual Read			
Haemophilus influenzae		50	Clinical and Challenge Isolates Using the Auto and Manual Read Method				Between-site total isolates tested	360		
Reproducibility Isolates (4 sites) (3 x day for 3 days)		15 (540)	Clinical and Challenge Isolates Combined Number of		Between-site isolates within +/- 1 well from mode	360				
Streptococcus spp. Haemophilus influenzae		10 (360)	Eravacycline	Isolates	Essential Agreement %		Between-site reproducibility ratio	360		
			Organism Group	<u>Total</u>	Auto Read	Manual Read	Between-site reproducibility %	100%		
ATCC Quality Control Strains (20+ replicates of each strain at 4 sites) Streptococcus spp.		1 (80)	Streptococcus pyogenes	120	98.3%	99.2%	Total essential agreement	360/360		
Haemophilus influenzae		1(80)	Streptococcus agalactiae	126	100%	100%				
OTAL		2158 (tests)	Streptococcus anginosus Group	67	100%	97.0%	Essential agreement %	<u>1</u>	<u>00%</u>	
		Streptococcus mitis	58 (*57)	98.2%	98.3%	Conclusions				
Quality Control ●Recommended CLSI quality control (QC) organisms were tested daily and were within the			Streptococcus salivarius	34	100%	100%	This study validates that the Sensititre 18–24 hour susceptibility system demonstrated an			
CLSI expected QC ranges.		Streptococcus pneumoniae	250	99.6%	99.6%	equivalent level of performance compared to the CLSI M07/M100 reference broth microdilution plate when testing eravacycline against <i>Streptococcus</i> spp. and <i>Haemophilus influenzae</i> clinical and challenge isolates. This study suggests that this is an acceptable method for susceptibility testing of eravacycline .				
 Colony counts were performed and fell within expected ranges Reference 2-8X10⁵, Sensititre 5X10⁴-5X10⁵ 			Total	655	99.4%				99.2%	
			*No MIC for Streptococcus mitis isolate MC447 (Optiread did not signal)			References				
able 2. Quality Control Strains	CLSI QC Ran	ges (µg/ml)	Table 4. Summary Data and % Essential Agreement of Haemophilus influenzae Clinical and Challenge Isolates Using the Manual Read Method				Clinical and Laboratory Standards Institute. 2015. <i>Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-tenth edition.</i> Approved document M07-A10. Wayne, PA: CLSI.			
ptococcus pneumoniae ATCC 49619 0.004-0.03µg/ml			Clinical and Challenge Isolates Combined				Clinical and Laboratory Standards Institute. 2018. Performance Standards for Antimicrobial			
laemophilus influenzae ATCC 49247 0.06-0.5µ		µg/ml	ml		Essential Agreement %		Susceptibility Testing; Twenty-seventh Informational Supplement M100-S28. Wayne, PA: CL FDA Guidance for Industry and FDA Class II Special Controls Guidance Document:			
			Organism Group	<u>Total</u>	Manua	Il Read	Antimicrobial Susceptibility Test (AST) Systems, August 28,			
			Haemophilus influenzae	443	4	37				
		Total	443	98.6% © 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.						

Nicole M. Holliday Supervisor AST/Pharma R&D **Thermo Fisher Scientific** Oakwood Village, OH 44146 1-800-871-8909 ext. 322-4319 nicole.holliday@thermofisher.com